FY26 Revenue Surge, US Tariff Margin Uncertainty

Advanced Enzyme Technologies Limited — Q4 & FY26 Earnings Call (Quarter ended Mar 31, 2026)

1. Overall Tone of Management: Optimistic

• Management highlights “highest-ever quarterly and annual revenue” and “excellent momentum” with strong profitability.
• Forward-looking language is confident but still hedged on macro/US: “confident that this steady momentum will continue” and “business outlook remains extremely steady,” while also calling FY27 “very challenging” due to US inflation/tariffs uncertainty.

2. Key Themes from Management Commentary

• Strong FY26 performance with operating leverage
• Q4 revenue INR 2,034m (+22% YoY; +18% QoQ) and EBITDA margin 31%.
• FY26 revenue INR 7,458m (+17% YoY); EBITDA margin 31%; PAT margin improved to 23%.
• Growth breadth across segments
• Human Healthcare remains largest (Q4 revenue INR 1,281m, +24% YoY).
• Bioprocessing: food business strong (+20% YoY), non-food near-flat/slightly down.
• Specialized manufacturing: +17% YoY; +16% QoQ.
• Regulatory progress supporting medium-term growth
• Filed 2 EFSA food enzyme dossiers and 3 US FDA dossiers during the year.
• Nashik R&D center expected to become operational in 2H FY26 (management language implies near-term ramp).
• “anticipating approval” of anti-inflammatory products filed two years back in Europe.
• Macro and cost pressure acknowledged, but mitigated via productivity
• Management repeatedly references geopolitical disruption, logistics inflation, and input cost uncertainty.
• Mitigation approach: “increase the productivity, increase the efficiencies and try to reduce the cost.”
• US market remains the key swing factor
• US is described as facing “enormous pressure” and “very challenging year,” but management expects “steady/same margins” and “growth in U.S. market also.”

3. Q&A Analysis

Theme A: Gross margin moderation vs EBITDA strength

• Core question(s):
• Why did gross margin moderate QoQ even as EBITDA margin increased?
• Is Serratiopeptidase run-rate sustainable?
• Management response:
• Explained as variable vs fixed cost / operating leverage and productivity improvements.
• Also suggested quarter-to-quarter variability and that multiple products contribute, not only inflammatory products.
• For Serratiopeptidase: “we’ll retain most of it” but “won’t comment on that” for exact run-rate.
• Evasive/partial elements:
• When pressed on gross margin mechanics, management deferred: “You can take last quarter… extraordinary items” then later “can take this offline.”
• EU market sizing and 5-year aspiration for the product were declined: “We cannot” / “I can’t comment.”

Theme B: US business outlook, tariffs, and margin risk

• Core question(s):
• US revenue down ~11% in INR terms—what’s happening post-tariff expectations?
• Will US slowdown continue for FY27? Any margin impact?
• Current tariff pass-through and whether they’re absorbing costs.
• Management response:
• US market dynamics: more focus on deliverable registration/studies; “market is changing.”
• Expected little growth from US but “not like the negative growth.”
• Margin: “same margins… 1% or 2% is always possible.”
• Tariffs: described as ongoing “drama” and “gradual process to pass it on,” while “to a certain extent, yes” they are absorbing ~“10-odd percentage cost.”
• Evasive/partial elements:
• No quantitative FY27 US revenue or margin guidance; reliance on qualitative “steady/same margins.”
• Tariff discussion avoided specifics on pass-through timing (“difficult to pass on… competitive world”).

Theme C: India growth drivers (pricing vs volume)

• Core question(s):
• Is Serratiopeptidase growth in India volume-driven or price-driven after prior pricing pressure?
• Any one-time India revenue component in Q4?
• Management response:
• Pricing “more or less constant,” growth mainly volume-driven.
• Explicit denial of one-time effects: “No, there is no that kind of revenue.”
• Notable clarity:
• Management directly addressed pricing vs volume and provided a consistent narrative.

Theme D: R&D center ramp, hiring, and Capex

• Core question(s):
• Incremental R&D expenses and hiring plan for Nashik R&D center.
• Capacity utilization and whether other R&D centers will be closed.
• Fermentation capacity expansion timing.
• Management response:
• Hiring: some already hired; some shifted; phased ramp; “intend to increase… by the threefold” of current capacity in first phase.
• R&D spend: absolute increase guidance given:
  • “R&D revenue expenditure… likely to go up by INR 50 million”
  • Capex: “additional… INR 50 crores… overall CapEx… about INR 130 crores”
• No closure of other R&D centers: “We will not be closing.”
• Fermentation capacity: infrastructure ready; capacity increment “by 50% right away”; expansion call in September.
• Strong specificity:
• Capex and incremental R&D numbers were among the clearest quantitative items in the call.

Theme E: Serratiopeptidase contribution and disclosure limits

• Core question(s):
• How much Serratio contributed to full-year and last year YoY growth?
• Competitive intensity and whether competitors are muted.
• Management response:
• Provided YTD growth and QoQ growth, but then limited future disclosure:
  • “on YTD growth about 45%, and QoQ… about 54%”
  • “This is the last time we will be sharing this number” (to avoid creating pressure on the product by competitors).
• Notable:
• This is unusually defensive/strategic in disclosure behavior.

Theme F: Adjacent growth areas (biocatalysis, non-meat proteins/peptides)

• Core question(s):
• Updates on biocatalysis trials and timeline to commercialization.
• Opportunities in peptides / non-meat proteins and whether they’re considering expansion.
• Management response:
• Biocatalysis: “trial are going well,” “moderate growth… this year,” but no product-level timelines.
• Peptides: “very interesting opportunity… exploring.”
• Non-meat proteins: “protein overall category is a growth category… continuously working… take advantage…**”
• Evasive elements:
• No quantified pipeline conversion timeline; repeated “many products/projects” framing.

4. Guidance / Outlook

Explicit guidance (quantitative)

• FY27 growth / margins (qualitative but with numeric anchors):
• Management repeatedly frames FY27 as “steady/same margins”.
• Analyst follow-ups elicited:
  • Margin variability: “1% or 2% is always possible.”
• Capex / R&D (quantitative)
• Capex: “additional… INR 50 crores… overall CapEx on R&D will be about INR 130 crores.”
• Incremental R&D revenue expenditure: “likely to go up by INR 50 million.”
• R&D center ramp: “threefold… in the first phase” (capacity, not spend).

Implicit signals (qualitative)

• US outlook: “very challenging year,” US expected “little growth… not negative.”
• Demand/macro: management expects enzyme adoption tailwinds but warns input cost and energy/logistics uncertainty.
• Product strategy: continued focus on R&D-driven innovation and new launches, but avoids single-product numeric targets.

5. Standout Statements (most revealing)

• Performance confidence
• “highest-ever quarterly and annual revenue”
• “business outlook remains extremely steady”
• US challenge framing
• “This is going to be a very challenging year no matter what”
• “enormous pressure of the inflationary pressures here in the U.S. economy due to energy”
• Margin stance
• “we will go with the same margins” (with “1% or 2%” variability)
• Disclosure limitation
• “This is the last time we will be sharing this number” (Serratiopeptidase growth metrics)
• R&D ramp specificity
• “expenses… go up… not like we will try to maintain between the whatever the current percentage”
• “increase… by the threefold” (capacity phase 1)
• “overall CapEx… about INR 130 crores”
• EU exclusivity narrative
• If approved: “we will be the only person who can supply that product for next five years or ten years” (no numbers provided)

6. Red Flags / Positive Signals

Positive signals
– Strong profitability metrics: EBITDA margin 31% maintained; PAT margin improved to 23%.
– Clear operational mitigation approach: productivity/efficiency to offset inflation.
– R&D and Capex plans are quantified and tied to ramp timing (2H FY26 operationalization; phased hiring).

Red flags
– US guidance is non-quantitative despite being a major swing factor; management uses “steady/same margins” while acknowledging “very challenging year.”
– Gross margin explanation was partially deferred (“take this offline”)—suggests less transparency on QoQ gross margin drivers.
– Multiple “we cannot / I won’t comment” responses on product-level EU market sizing and 5-year aspirations.
– Serratiopeptidase disclosure capped due to competitive pressure—could also indicate sensitivity around sustainability.

7. Historical Comparison & Consistency Analysis (vs prior 3 calls)

a. Change in Tone Over Time

• Current call (Q4/FY26): More Optimistic
• Strong celebratory framing (“highest-ever revenue,” “excellent momentum,” “confident momentum will continue”).
• Prior calls:
• Q3/FY26 (Feb 2026): tone was mixed; management said “performance was mixed” and EBITDA down QoQ/Yoy.
• Q2/FY26 (Nov 2025): optimistic growth across segments; still acknowledged tariff uncertainty.
• Q1/FY26 (Aug 2025): optimistic but acknowledged “temporary dip” in bioprocessing and tariff murkiness.
• Shift driver: FY26 exit shows margin resilience and PAT growth, enabling more confidence.

b. Tracking Past Commitments vs Outcomes

• R&D center operationalization
• Prior: Q1 FY26 said R&D facility expected in last quarter of FY26; Q3 FY26 discussions implied commissioning timelines.
• Current: Nashik R&D center expected to become fully operational in 2H FY26.
• Assessment: ✅/⏳ Mostly on track (current call aligns with “2H FY26” rather than slipping far).
• US tariff impact / margin impact
• Prior (Q2 FY26): worst-case EBITDA impact ~2%.
• Current: still references absorption and “1% or 2%” variability; consistent direction.
• Assessment: ✅ Consistency on magnitude of margin risk.
• Serratiopeptidase run-rate
• Prior calls: management often avoided run-rate commitments and emphasized variability.
• Current: again avoids product-level guidance; says “retain most of it” but “won’t comment” on run-rate.
• Assessment: ✅ No new overpromising; still cautious.

c. Narrative Shifts

• From “tariff uncertainty” to “steady momentum”
• Earlier calls emphasized uncertainty and “wait and watch.”
• Now, management leans more on operational execution and R&D/regulatory progress.
• US story remains but is reframed
• Earlier: tariffs were the main culprit.
• Current: adds regulatory deliverables/studies concentration and “market changing,” not just tariffs.
• Gross margin narrative
• Earlier: gross margin volatility attributed to inventory valuation true-ups and product mix.
• Current: still product mix/variable vs fixed cost, but QoQ gross margin question was partially deferred.

d. Consistency & Credibility Signals

• Medium credibility
• Strength: consistent margin range language (“~30–32% EBITDA” and “1–2% variability”).
• Weakness: repeated deferrals on product-level quantification (EU market size, Serratio run-rate) and at least one “offline” deflection on gross margin mechanics.
• No clear pattern of acknowledging misses with corrective action; instead, management emphasizes mitigation.

e. Evolution of Key Themes

• Demand / adoption: improving narrative—enzyme adoption tailwind emphasized more strongly in FY26 exit.
• Margins: stable at ~31% EBITDA; gross margin volatility persists but is explained as mix/operational factors.
• Expansion: shift toward R&D center + regulatory dossiers and phased capacity expansion decisions (September call).
• US risk: remains persistent; now includes regulatory process changes and discretionary spending pressure.

f. Additional Insights (cross-period)

• The company’s US weakness appears to be increasingly attributed to commercial/regulatory execution (deliverable registrations, studies) rather than only tariff math—this could imply a longer normalization period than investors expect.
• Management’s decision to stop sharing Serratiopeptidase growth numbers suggests competitive sensitivity; sustainability may be harder to defend publicly than management’s “steady momentum” suggests.